Over the past 12 months, 8 insiders at Nuvalent, Inc. filed 175 open-market SEC Form 4 transactions on NUVL: 0 purchases worth $0 and 175 sales worth $102.6M. Insiders have been net sellers over this period. The most recent filing was on Jul 9, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 9, 26 | Henry E. PelishChief Scientific Officer | SELL | 2.1K | $123.81 | $261K |
| Jul 6, 26 | James Richard PorterPresident and CEO | SELL | 30.0K | $123.72 | $3.7M |
| Jul 1, 26 | Alexandra BalcomChief Financial Officer | SELL | 11.4K | $123.58 | $1.4M |
| Jul 1, 26 | Darlene NociChief Development Officer | SELL | 23.0K | $123.59 | $2.8M |
| Jun 1, 26 | Alexandra BalcomChief Financial Officer | SELL | 3.1K | $103.84 | $313K |
| May 1, 26 | Alexandra BalcomChief Financial Officer | SELL | 7.4K | $99.97 | $738K |
| Mar 26, 26 | Deborah Ann MillerChief Legal Officer | SELL | 2.8K | $99.46 | $279K |
| Mar 25, 26 | Alexandra BalcomChief Financial Officer | SELL | 13.7K | $100.16 | $1.4M |
| Mar 24, 26 | Alexandra BalcomChief Financial Officer | SELL | 7.7K | $96.50 | $735K |
| Mar 13, 26 | Henry E. PelishChief Scientific Officer | SELL | 2.6K | $99.71 | $257K |
| Mar 12, 26 | Henry E. PelishChief Scientific Officer | SELL | 24.2K | $99.12 | $2.4M |
| Mar 6, 26 | James Richard PorterPresident and CEO | SELL | 16.0K | $100.19 | $1.6M |
| Feb 26, 26 | Deborah Ann MillerChief Legal Officer | SELL | 2.7K | $103.96 | $277K |
| Feb 26, 26 | Darlene NociChief Development Officer | SELL | 3.0K | $104.25 | $308K |
| Jan 29, 26 | Darlene NociChief Development Officer | SELL | 3.4K | $103.39 | $349K |
| Jan 22, 26 | Deborah Ann MillerChief Legal Officer | SELL | 14.3K | $110.16 | $1.6M |
| Jan 21, 26 | Deborah Ann MillerChief Legal Officer | SELL | 700 | $109.84 | $77K |
| Jan 6, 26 | Alexandra BalcomChief Financial Officer | SELL | 1.6K | $98.40 | $159K |
| Jan 6, 26 | Deborah Ann MillerChief Legal Officer | SELL | 1.3K | $98.40 | $130K |
| Jan 6, 26 | Darlene NociChief Development Officer | SELL | 1.6K | $98.40 | $159K |
| Jan 6, 26 | Henry E. PelishChief Scientific Officer | SELL | 1.4K | $98.40 | $133K |
| Jan 6, 26 | James Richard PorterPresident and CEO | SELL | 4.9K | $98.40 | $477K |
| Jan 6, 26 | Christopher Durant TurnerChief Medical Officer | SELL | 1.6K | $98.40 | $159K |
| Jan 5, 26 | Alexandra BalcomChief Financial Officer | SELL | 1.9K | $98.52 | $189K |
| Jan 5, 26 | Deborah Ann MillerChief Legal Officer | SELL | 2.0K | $98.52 | $195K |
| Jan 5, 26 | Darlene NociChief Development Officer | SELL | 1.9K | $98.52 | $189K |
| Jan 5, 26 | Henry E. PelishChief Scientific Officer | SELL | 1.1K | $98.52 | $111K |
| Jan 5, 26 | James Richard PorterPresident and CEO | SELL | 8.1K | $98.52 | $798K |
| Jan 5, 26 | Christopher Durant TurnerChief Medical Officer | SELL | 1.9K | $98.52 | $189K |
| Jan 2, 26 | Deborah Ann MillerChief Legal Officer | SELL | 5.5K | $101.47 | $550K |
| Dec 30, 25 | Darlene NociChief Development Officer | SELL | 3.4K | $101.22 | $335K |
| Dec 8, 25 | Alexandra BalcomChief Financial Officer | SELL | 7.0K | $111.32 | $770K |
| Nov 28, 25 | Darlene NociChief Development Officer | SELL | 3.4K | $108.72 | $365K |
| Nov 24, 25 | James E FlynnDirector,TenPercentOwner,Other | SELL | 371.3K | $95.45 | $35.4M |
| Nov 24, 25 | Matthew ShairDirector | SELL | 2.3K | $110.42 | $246K |
| Nov 18, 25 | Alexandra BalcomChief Financial Officer | SELL | 509 | $104.54 | $53K |
| Nov 17, 25 | Alexandra BalcomChief Financial Officer | SELL | 5.1K | $103.68 | $522K |
| Nov 17, 25 | Deborah Ann MillerChief Legal Officer | SELL | 15.1K | $107.04 | $1.6M |
| Oct 30, 25 | Deborah Ann MillerChief Legal Officer | SELL | 9.4K | $104.78 | $983K |
| Oct 30, 25 | Darlene NociChief Development Officer | SELL | 1.2K | $104.58 | $119K |
| Oct 28, 25 | Matthew ShairDirector | SELL | 32.5K | $100.27 | $3.3M |
| Oct 27, 25 | Matthew ShairDirector | SELL | 14.3K | $100.23 | $1.4M |
| Oct 20, 25 | Deborah Ann MillerChief Legal Officer | SELL | 5.0K | $94.91 | $475K |
| Oct 16, 25 | James Richard PorterPresident and CEO | SELL | 13.9K | $92.63 | $1.3M |
| Oct 16, 25 | Deborah Ann MillerChief Legal Officer | SELL | 5.2K | $92.50 | $475K |
| Oct 15, 25 | Alexandra BalcomChief Financial Officer | SELL | 1.7K | $85.57 | $144K |
| Oct 15, 25 | Deborah Ann MillerChief Legal Officer | SELL | 15.6K | $89.98 | $1.4M |
| Oct 15, 25 | Henry E. PelishChief Scientific Officer | SELL | 14.2K | $90.04 | $1.3M |
| Oct 14, 25 | Alexandra BalcomChief Financial Officer | SELL | 12.3K | $88.90 | $1.1M |
| Oct 14, 25 | Henry E. PelishChief Scientific Officer | SELL | 1.2K | $87.39 | $99K |
Over the past 12 months, insiders at Nuvalent, Inc. filed 0 open-market purchases worth $0 and 175 sales worth $102.6M on NUVL, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 9, 26.
8 different insiders at Nuvalent, Inc. filed open-market SEC Form 4 transactions on NUVL over the last 12 months.
InsiderTape plots every NUVL insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Nuvalent, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →